Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pulse Biosciences (PLSE) Enterprise Value (2020 - 2025)

Pulse Biosciences has reported Enterprise Value over the past 6 years, most recently at -$95.2 million for Q3 2025.

  • Quarterly results put Enterprise Value at -$95.2 million for Q3 2025, down 20.47% from a year ago — trailing twelve months through Sep 2025 was -$95.2 million (down 20.47% YoY), and the annual figure for FY2024 was -$118.0 million, down 166.06%.
  • Enterprise Value for Q3 2025 was -$95.2 million at Pulse Biosciences, up from -$106.3 million in the prior quarter.
  • Over the last five years, Enterprise Value for PLSE hit a ceiling of -$12.7 million in Q1 2022 and a floor of -$119.3 million in Q1 2025.
  • Median Enterprise Value over the past 5 years was -$54.1 million (2023), compared with a mean of -$59.4 million.
  • Biggest five-year swings in Enterprise Value: crashed 453.73% in 2021 and later surged 78.83% in 2022.
  • Pulse Biosciences' Enterprise Value stood at -$44.4 million in 2021, then crashed by 37.81% to -$61.1 million in 2022, then increased by 27.44% to -$44.4 million in 2023, then crashed by 166.06% to -$118.0 million in 2024, then grew by 19.34% to -$95.2 million in 2025.
  • The last three reported values for Enterprise Value were -$95.2 million (Q3 2025), -$106.3 million (Q2 2025), and -$119.3 million (Q1 2025) per Business Quant data.